This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
payments: Archive
Marsh Raises Dividend: Is Its Capital Return Story Getting Stronger?
by Zacks Equity Research
MRSH raises its quarterly dividend 10% to 99 cents per share, highlighting strong cash generation and a continued focus on rewarding shareholders.
MRSHNegative Net Change DAVENegative Net Change GDOTNegative Net Change GDSPositive Net Change
business-services fin-tech finance insurance payments
Can Visa's Multi-Rail Payments Strategy Drive Long-Term Growth?
by Piyali Saha Sikdar
Visa's multi-rail payments strategy is expanding beyond cards with faster transfers, AI and digital currency support, helping drive revenue growth and future opportunities.
VNegative Net Change MANegative Net Change AXPNegative Net Change
business-services fin-tech payments
Will Mastercard's Click to Pay Gain Traction With stc pay?
by Rajshree Sipani
MA expands Click to Pay with stc pay Bahrain, aiming to speed secure online checkouts through tokenization and biometric authentication.
MANegative Net Change VNegative Net Change AXPNegative Net Change
business-services fin-tech finance payments
Bassett Furniture (BSET)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BSETPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
LATAM (LTM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
LTMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Mastercard Beyond Cards: Is It Winning the Multi-Rail Game?
by Rajshree Sipani
MA is expanding beyond cards with a multi-rail payments strategy, driving growth in services and money movement as payment preferences evolve.
MANegative Net Change VNegative Net Change AXPNegative Net Change
artificial-intelligence automation blockchain business-services fin-tech finance payments
Top Mobile Payments Stocks to Buy as Cashless Commerce Accelerates
by Kaibalya Pravo Dey
Mobile payments are reshaping global commerce. See why V, XYZ, KLAR and GDOT could be among the biggest beneficiaries.
VNegative Net Change GDOTNegative Net Change XYZNegative Net Change KLARNegative Net Change
artificial-intelligence fin-tech finance payments
Trio of Economic Data Signal Slow But Steady Expansion
by Mayur Thaker
Steady as she goes as semiconductors continue to carry the market momentum in both price and earnings.
VNegative Net Change GDOTNegative Net Change XYZNegative Net Change KLARNegative Net Change
payments
Heico Corporation (HEI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
HEIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
by Zacks Equity Research
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
RHHBYPositive Net Change BMYPositive Net Change AMGNPositive Net Change NRIXPositive Net Change
biotechnology biotechs medical payments